Form 4 for BMRN BIOMARIN PHARMACEUTICAL INC
Accepted 2024-11-14 00:00:00 ET · period of report 2024-11-12 · accession 0001048477-24-000154 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-14 | 2024-10-31 | BMRN | Guyer Charles Greg | EVP, Chief Technical Off | A - Grant | $56.01 | +55 | 74.2K | +0.1% | +$3,081 | |
| 2024-11-14 | 2024-11-12 | BMRN | Guyer Charles Greg | EVP, Chief Technical Off | S - Sale | $66.37 | -5,278 | 68.9K | -7% | -$350.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-31 | A | A | 55 | $56.01 | 74,187 | D | — | — | (F1) Represents the shares acquired by the reporting person on October 31, 2024, pursuant to the issuer's Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2024-11-12 | S | D | 5,278 | $66.37 | 68,909 | D | — | — | (F2) The price in column 4 is the weighted average price. The purchase price actually received ranged from $66.37 to $66.395. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. |